Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has be...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | World Allergy Organization Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455122000977 |
| _version_ | 1811292840654798848 |
|---|---|
| author | Diego Bagnasco, MD, PhD Rikki Frank Canevari, MD Stefano Del Giacco, MD Silvia Ferrucci, MD Paolo Pigatto, MD Paolo Castelnuovo, MD Gian Luigi Marseglia, MD Arzu Didem Yalcin, MD Girolamo Pelaia, MD Giorgio Walter Canonica, MD |
| author_facet | Diego Bagnasco, MD, PhD Rikki Frank Canevari, MD Stefano Del Giacco, MD Silvia Ferrucci, MD Paolo Pigatto, MD Paolo Castelnuovo, MD Gian Luigi Marseglia, MD Arzu Didem Yalcin, MD Girolamo Pelaia, MD Giorgio Walter Canonica, MD |
| author_sort | Diego Bagnasco, MD, PhD |
| collection | DOAJ |
| description | Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has been recently linked to potential increased cancer risk. Nevertheless, literature evidence does not support this statement, and clinical studies and evidence from real-world registries and surveillance analysis have consistently reported drug safety. |
| first_indexed | 2024-04-13T04:52:36Z |
| format | Article |
| id | doaj.art-7f6545a21c024b7687afd08bc6b36dce |
| institution | Directory Open Access Journal |
| issn | 1939-4551 |
| language | English |
| last_indexed | 2024-04-13T04:52:36Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj.art-7f6545a21c024b7687afd08bc6b36dce2022-12-22T03:01:38ZengElsevierWorld Allergy Organization Journal1939-45512022-12-011512100721Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polypsDiego Bagnasco, MD, PhD0Rikki Frank Canevari, MD1Stefano Del Giacco, MD2Silvia Ferrucci, MD3Paolo Pigatto, MD4Paolo Castelnuovo, MD5Gian Luigi Marseglia, MD6Arzu Didem Yalcin, MD7Girolamo Pelaia, MD8Giorgio Walter Canonica, MD9Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), University of Genoa, Italy; IRCCS Policlinico San Martino, Genoa, Italy; Corresponding author. Allergy and Respiratory Diseases, IRCCS San Martino, University of Genoa, Genoa, ItalyIRCCS Policlinico San Martino, Genoa, Italy; Unit of Otorhinolaryngology-Head and Neck Surgery, University of Genoa, Genoa, ItalyDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, ItalyDepartment of Clinical Sciences and Community Health, University of Milan, Milan, ItalyClinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, ItalyDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Ospedale di Circolo e Fondazione Macchi, Varese, ItalyPediatric Clinic, Fondazione IRCCS Policlinico “S. Matteo,” University of Pavia, Pavia, ItalyDivision of Allergy and Immunology, Department of Internal Medicine, Antalya Education and Research Hospital, University of Health Sciences, Antalya, TurkeyDepartment of Health Sciences, Magna Graecia University, Catanzaro, ItalyPersonalized Medicine Center, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, ItalyOmalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has been recently linked to potential increased cancer risk. Nevertheless, literature evidence does not support this statement, and clinical studies and evidence from real-world registries and surveillance analysis have consistently reported drug safety.http://www.sciencedirect.com/science/article/pii/S1939455122000977Severe asthmaOmalizumabCancerAnti IgEMonoclonal antibodies |
| spellingShingle | Diego Bagnasco, MD, PhD Rikki Frank Canevari, MD Stefano Del Giacco, MD Silvia Ferrucci, MD Paolo Pigatto, MD Paolo Castelnuovo, MD Gian Luigi Marseglia, MD Arzu Didem Yalcin, MD Girolamo Pelaia, MD Giorgio Walter Canonica, MD Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps World Allergy Organization Journal Severe asthma Omalizumab Cancer Anti IgE Monoclonal antibodies |
| title | Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps |
| title_full | Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps |
| title_fullStr | Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps |
| title_full_unstemmed | Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps |
| title_short | Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps |
| title_sort | omalizumab and cancer risk current evidence in allergic asthma chronic urticaria and chronic rhinosinusitis with nasal polyps |
| topic | Severe asthma Omalizumab Cancer Anti IgE Monoclonal antibodies |
| url | http://www.sciencedirect.com/science/article/pii/S1939455122000977 |
| work_keys_str_mv | AT diegobagnascomdphd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT rikkifrankcanevarimd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT stefanodelgiaccomd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT silviaferruccimd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT paolopigattomd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT paolocastelnuovomd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT gianluigimarsegliamd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT arzudidemyalcinmd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT girolamopelaiamd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps AT giorgiowaltercanonicamd omalizumabandcancerriskcurrentevidenceinallergicasthmachronicurticariaandchronicrhinosinusitiswithnasalpolyps |